FDA Approves Lumryz for Narcolepsy
THURSDAY, May 4, 2023 -- The U.S. Food& Drug Administration has approved Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Lumryz is an extended-release formulation of sodium oxybate to be taken... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2023 Category: Pharmaceuticals Source Type: news
FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy
Extended-release sodium oxybate (Lumryz) is taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 2, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
DUBLIN, May 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S. Food& Drug Administration (FDA) has granted... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 1, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Grants Final Approval of Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
DUBLIN, May 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S. Food& Drug Administration (FDA) has granted... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 1, 2023 Category: Drugs & Pharmacology Source Type: news
Harmony BioSciences' shares fall following critical short-seller report
A short-seller raised questions about the company's narcolepsy drug; Harmony "disagrees with their assertions." (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 29, 2023 Category: Biotechnology Authors: John George Source Type: news
Pitolisant Safe and Effective in Children With Narcolepsy
(MedPage Today) -- Pitolisant (Wakix) in children ages 6 years and up led to clinically meaningful improvements in narcolepsy symptoms in a phase III trial.
Among 110 kids with narcolepsy with or without cataplexy, excessive daytime sleepiness... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 25, 2023 Category: Neurology Source Type: news
Family Builds Empire Off 'Christian' Insurance; Narcolepsy Drug Patent Games
(MedPage Today) -- Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week.
Family Builds Empire Off 'Christian' Insurance
Liberty HealthShare, a nonprofit known as... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 1, 2023 Category: American Health Source Type: news
Jazz Pharma Ruling Clears US Roadblock for Rival Narcolepsy Drug Jazz Pharma Ruling Clears US Roadblock for Rival Narcolepsy Drug
A US appeals court ordered Jazz Pharmaceuticals on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the FDA ' s register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Harmony Biosciences profits soar on surging sales of narcolepsy drug
The company has grown to 220 employees and expects to hire as many as 20 more this year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 21, 2023 Category: Pharmaceuticals Authors: John George Source Type: news
The forgotten victims of the Adderall shortage
Dion Lee/Vox People with narcolepsy need stimulants, too. But many pharmacy shelves are empty. Kelsey can’t do her job without her medication. The resident physician in Wisconsin, who is in her early 30s, takes the generic version of a stimulant called Concerta to treat her narcolepsy as well as…#kelsey #wisconsin #concerta #ritalin #narcolepsy #keithharper #narcolepsynetwork #tiktok #rem #hypersomnia (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2023 Category: Consumer Health News Source Type: news
Latest partnership in Japan to use wearables in studying sleep disorders
They seek to identify digital predictive biomarkers of narcolepsy and excessive daytime sleeping. (Source: mobihealthnews)
Source: mobihealthnews - January 26, 2023 Category: Information Technology Source Type: news
Psychomotor vigilance performance in participants with excessive daytime sleepiness in obstructive sleep apnea or narcolepsy compared with SAFTE-FAST model predictions - Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, Donjacour CEHM, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, Lammers GJ.
INTRODUCTION: Excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) can impair vigilance/attention. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved to treat EDS associated with narcolepsy (75... (Source: SafetyLit)
Source: SafetyLit - December 12, 2022 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Effects of solriamfetol on on-the-road driving in participants with narcolepsy: a randomised crossover trial - Vinckenbosch F, Lammers GJ, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A.
OBJECTIVE: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving performance in participants with narcolepsy. METHODS: In this randomised, double-blind, placebo-controlled, crossover study,... (Source: SafetyLit)
Source: SafetyLit - November 30, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Not only excessive daytime sleepiness but also depression symptoms, chronological age and onset-age were associated with impulsivity in narcolepsy Type 1 patients - Yang Y, Zhang J, Han F, Xiao F.
OBJECTIVE: To detect the factors associated with total and subscales impulsivity scores in narcolepsy and further explore the non-linear relationship between these factors and impulsivity score. METHODS: One hundred and fifty-eight narcolepsy type ... (Source: SafetyLit)
Source: SafetyLit - October 26, 2022 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
FDA Says ADHD Medication Adderall Is in Short Supply
THURSDAY, Oct. 13, 2022 -- People with attention-deficit/hyperactivity disorder (ADHD) or narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.
The Adderall and Adderall IR... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 13, 2022 Category: Pharmaceuticals Source Type: news
